首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation
【2h】

Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation

机译:高雪氏病中的突变型葡萄糖脑苷脂酶将Hsp27募集到Hsp90分子伴侣复合物中进行蛋白酶体降解

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Gaucher disease is caused by mutations of the GBA1 gene, which encodes the lysosomal anchored gluococerebrosidase (GCase). GBA1 mutations commonly result in protein misfolding, abnormal chaperone recognition, and premature degradation, but are less likely to affect catalytic activity. In the present study, we demonstrate that the Hsp90/HOP/Cdc37 complex recruits Hsp27 after recognition of GCase mutants with subsequent targeting of GCase mutant peptides to degradation mechanisms such as VCP and the 26S proteasome. Inhibition of Hsp27 not only increased the quantity of enzyme but also enhanced GCase activity in fibroblasts derived from patients with Gaucher disease. These findings provide insight into a possible therapeutic strategy for protein misfolding diseases by correcting chaperone binding and altering subsequent downstream patterns of protein degradation.
机译:高雪氏病是由GBA1基因突变引起的,该基因编码溶酶体锚定的葡糖脑苷脂酶(GCase)。 GBA1突变通常会导致蛋白质错误折叠,异常的伴侣识别和过早降解,但影响催化活性的可能性较小。在本研究中,我们证明了Hsp90 / HOP / Cdc37复合体在识别GCase突变体后,随后将GCase突变体肽靶向降解机制(例如VCP和26S蛋白酶体)募集了Hsp27。 Hsp27的抑制不仅增加了来自高雪氏病患者的成纤维细胞中的酶量,而且还增强了GCase活性。这些发现通过校正分子伴侣结合和改变蛋白质降解的下游模式,为蛋白质错误折叠疾病的可能治疗策略提供了见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号